Hitoshi Sasano, Norihiro Harada, Sonoko Harada, Tomohito Takeshige, Yuuki Sandhu, Yuki Tanabe, Ayako Ishimori, Kei Matsuno, Tetsutaro Nagaoka, Jun Ito, Asako Chiba, Hisaya Akiba, Ryo Atsuta, Kenji Izuhara, Sachiko Miyake, Kazuhisa Takahashi
BACKGROUND: Mepolizumab treatment improves symptom control and quality of life and reduces exacerbations in patients with severe eosinophilic asthma. However, biomarkers that predict therapeutic effectiveness must be determined for use in precision medicine. Herein, we elucidated the dynamics of various parameters before and after treatment as well as patient characteristics predictive of clinical responsiveness to mepolizumab after 1-year treatment. METHODS: Twenty-seven patients with severe asthma were treated with mepolizumab for one year...
June 17, 2023: Allergology International: Official Journal of the Japanese Society of Allergology